Exabis Library
Welcome to the e-CCO Library!
P0619: Comparative efficacy of all available pharmaceutical therapies for moderate to severe Crohn’s disease: a systematic review and network meta-analysis.
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P061: Circulating inflammatory protein and cellular profiles at time of diagnosis classify inflammatory bowel disease patients according to their underlying immune response and clinical disease course
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P061: Creeping fat contains a unique T-cell compartment with potential impact on intestinal inflammation
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P061: Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease – IBD Character
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P061: Immune cell infiltrations of myenteric plexus in IBD – characterization and implications
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P061: Probiotic kimchi prevented colitis-associated cancer
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P061: Response to anti-α4β7 therapy in Ulcerative colitis is associated with lymphoid aggregate attrition through impaired recruitment of naïve lymphocytes
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P061: Succinate promotes EMT in intestinal epithelial cells through SUCNR1: Relevance in fistula development
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P062 Dose-dependent differential effects of vedolizumab therapy on adhesion of regulatory and effector T cells
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P0620: Long-term impact of early medical prevention of postoperative recurrence on second intestinal resections in patients with Crohn’s Disease. Data from the ENEIDA registry.
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0621: Effectiveness and Safety of Induction Therapy with Upadacitinib for the Treatment of Perianal Crohn’s Disease : Real-World Data from a GETAID Multicentre Cohort Study.
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0622: Total emulsifier intakex7x7x7 but not ultra-processed food consumption is higher in patients with Inflammatory Bowel Disease compared to healthy controls
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0623: Vedolizumab clearance as a predictor of remission in inflammatory bowel disease: a real-world pharmacokinetic study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0624: Adherence to a Care Pathway for Inflammatory Bowel Disease in the Southwest region of the Netherlands
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0625: Impact of TMPT genotype on Azathioprine side effects and durability in a cohort of pediatric patients with Inflammatory Bowel Diasease: a real life study.
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0626: One year outcomes of upadacitinib in Crohn’s disease in a large real-world cohort.
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0627: Pharmacokineticsx7x7x7 Pharmacodynamicsx7x7x7 Safetyx7x7x7 and Efficacy of Oral Resolvin E1-based Therapy in Inflammatory Bowel Disease (IBD): Translating Resolvin E1 Activation of BLT1 in Experimental Models to Healthy Volunteers
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0628: Patient preferences towards treatment attributes in Inflammatory Bowel Disease: a Brazilian cohort study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0629: A scoping review of evidence-based dietary guidance and guidelines published by national and international organisations on Inflammatory Bowel Disease
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P062: 31P MRS and MRI phenotyping of muscle metabolic quality in IBD fatigue
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM